Playing a key role in developing
life-saving cancer immunotherapies
Playing a key role in developing life-saving cancer immunotherapies
Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
Findings point to new therapeutic strategy to maximize dendritic cell-induced T-cell activation with potential to benefit patients as a single agent and in combination with immune checkpoint inhibitors.
View Research ArticleResearchers discover new pathways to activate dendritic cells, produce strong anti-tumor immunity
Oncolytic virus expressing CD40 ligand and IFNβ reduces tumor size, activates immune cells in phase 1 trial
View Press Release
Clinical Trials Update Memgen is slated to begin clinical trials of MEM-288 in Spring 2022. Details coming soon.
Recent Tweets About Us
#memgen
While at #AACR23, we met up with Dr. Andreas N. Saltos to discuss a phase 1 first-in-human study of MEM-288 oncolytic virus in solid tumors including non-small cell lung cancer (NSCLC): impact on tumor and systemic T cell immunity. Read more ➡️ https://t.co/NBTcnXUIis @AACR pic.twitter.com/3j8hcCdfqH
— Moffitt Cancer Center (@MoffittNews) April 18, 2023
Our Mission
Fighting to Cure Cancer
Memgen's mission is to design and develop viral immunotherapies that can be used in combination with market-leading cancer drugs including KEYTRUDA and OPDIVO to cure cancer.
Learn MoreOur Technology
Viral Immunotherapies
Memgen has built a strong world-wide patent position around our viral immunotherapies which have been re-engineered to kill cancer cells, while sparing healthy cells. MEM-288 is scheduled to begin clinical trials in 2021.
Learn MoreLatest News
Memgen Announces FDA Clearance of IND Application for MEM-288
November 3, 2021 - MEM-288 to be studied in patients with cancers not responding to checkpoint inhibitors including non-small cell lung cancer and triple-negative breast cancer. Initiation of patient screening in Phase 1 study of MEM-288 expected by 12/31/2021
Read MoreLatest News
John Poulos, An Experienced Pharmaceutical Executive, Joins Memgen's Board of Directors
November 2020 - John Poulos has joined Memgen's Board of Directors. He previously led business development at AbbVie and Abbott and was instrumental in the negotiation and execution of many of the transactions that shaped AbbVie's business. With his extraordinary track record and his extensive network of C-level pharmaceutical relationships, John is ideally positioned to provide strong insight and strategic guidance to Memgen's business development and M&A efforts.
READ MORE
Management Team and Board of Directors
We have a track record of success in the biotechnology, pharmaceutical, and finance sectors.
Director
Extensive career bridging scientific and financial expertise in life sciences. Founder and Vice Chairman of HealthCare Royalty Partners (“HCR”). MBA from Harvard Business School, an MD from SUNY Upstate College of Medicine, and a BA from Yale University.
Director
Extensive research and industry experience in cancer immunotherapy drug discovery and development. Inventor on multiple patented technologies, including Memgen’s viral cancer immunotherapies. PhD in Biomedical Sciences from the University of California San Diego.
Chairman of the Board
Dr. Coates is the founder and lead investor in Memgen. MBA and PhD in Finance, Accounting, and Economics from the University of Chicago Graduate School of Business.
Chief Financial Officer of Tracon Pharmaceuticals 2014-18 where she oversaw Tracon’s $41 million IPO and subsequent financings totaling over $100 million. Previous experience includes senior accounting positions at NuVasive and Orexigen Therapeutics and various CFO/accounting consulting roles.
Senior Vice President, Corporate & Business Development at Travere Therapeutics. Prior to Travere, Chief Business Officer at Tracon Pharmaceuticals. Before joining Tracon held senior corporate development roles at Bird Rock Bio and Anadys Pharmaceuticals (acquired by Roche).
Former Chief Investment Officer, Chief Financial Officer, and Chief Risk Officer with Assurant, Inc. a NYSE-traded insurance company, over twenty-three years. MBA from the University of Chicago Graduate School of Business and a BS in Economics from the University of Pennsylvania Wharton School.
Deeply experienced pharmaceutical senior executive. Former Global Head of Corporate Development at Abbott and AbbVie, responsible for multiple major acquisitions, including Pharmacyclics ($21 billion) and Knoll/BASF ($6.9 billion).
Founding member of Wiltshire, Whitley, Richardson & English, PA, a full-service accounting firm offering a comprehensive range of business and personal accounting services. He is a member of the American Institute of Certified Public Accountants (AICPA) and the Florida Institute of Certified Public Accountants (FICPA).
Scientific Advisory Board
Our board provides the expertise and guidance necessary to develop our cancer immunotherapies.
Our Science
Memgen’s
CD40 Ligand
A patented, safe and effective biological.
Memgen is applying its expertise in immune-regulatory systems to develop a range of immunotherapies, including viral immunotherapies, cell-based immunotherapies (TILs), and infectious disease vaccine adjuvants. Our immunotherapies are designed with multimodal mechanisms of action capable of working as single agents or in combination with checkpoint inhibitors and other therapies to maximize therapeutic benefit with a desirable safety profile.
Memgen’s immunotherapies leverage the power of our proprietary clinically evaluated CD40 ligand in combination with other co-stimulatory genes. MEM-288, our lead product candidate, combines our CD40 ligand with interferon beta (IFNβ). This combination has been engineered by Memgen and Moffitt Cancer Center to provide the optimum capability to generate a robust, whole-body, tumor-targeted T cell immune response.
The combination of a highly active viral immunotherapy with two potent transgenes turns Memgen's MEM-288 into a “triple threat” attacking cancers with three discrete mechanisms.
Partnering
Memgen is actively seeking strategic partnership and business opportunities with pharmaceutical and biotechnology companies for expanded research and clinical development.
2023 SITC Annual Meeting
November 1-5, 2023 | San Diego, CA & Online
Memgen will be attending the 2023 SITC Annual Meeting in San Diego, CA & Online (November 1-5, 2023). We look forward to connecting with you.
JPM 2024 Annual Healthcare Conference
January 8-11, 2024 | San Francisco, CA
Memgen will be attending the JPM 2024 Annual Healthcare Conference in San Francisco, CA (January 8-11, 2024). We look forward to connecting with you.
Contact Us
Memgen's Headquarters
12 Greenway Plaza
Suite 1100
Houston, TX 77046
For company inquiries and partnering please contact:
Dr. Greg Brown, Memgen’s CEO
gbrown@memgenbio.com